Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0045-1802565
Original Article

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study

Dinesh Chandra Doval
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India
,
Tanveer Maksud
2   Department of Medical Oncology, Unique Hospital Multispecialty & Research Institute, Surat, Gujarat, India
,
Rajnish Nagarkar
3   Department of Surgical Oncology, HCG Manavata Cancer Centre, HCG Manavata Cancer Centre, Nashik, Maharashtra, India
,
Satheesh Chiradoni Thunagappa
4   Department of Medical Oncology, HCG Cancer Centre, Bengaluru, Karnataka, India
,
Rakesh Taran
5   Department of Medical Oncology, SRJ-CBCC Cancer Hospital, Indore, Madhya Pradesh, India
,
Saurabh Prasad
6   Department of Medical Oncology, Kingsway Hospital, Nagpur, Maharashtra, India
,
7   Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Minish Jain
8   Department of Medical Oncology, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India
,
Dhruv Mehta
9   Department of Medical Oncology, Nirmal Hospital Pvt. Ltd., Surat, Gujarat, India
,
Prabrajya Narayan Mohapatra
10   Department of Medical Oncology, Apollo Gleneagles Hospital, Salt Lake, Kolkata, West Bengal, India
,
Sachin Gupta
11   Department of Medical Oncology, Max Super Specialty Hospital, Chandigarh, India
,
Kritarth Naman Singh
12   Clinical Research Physician (Oncology), Eli Lilly and Company (India) Pvt. Ltd., Gurgaon, Haryana, India
,
Aarohan Pruthi
13   Senior Director - Medical (Oncology), Eli Lilly and Company (NAPAC), Sydney, Australia
,
Rohit Arora
14   Senior Director - Medical Development, Eli Lilly Services India Private Limited, Bangalore, Karnataka, India
› Author Affiliations
Trial Registration Numbers Clinicaltrials.gov - NCT04707196 and Clinical Trials Registry - India (CTRI) - CTRI/2020/12/030021.
Preview

Abstract

Background Global phase III trials demonstrated efficacy of abemaciclib in patients with HR +/HER2– metastatic breast cancer (BC) as a first-line therapy in combination with a nonsteroidal aromatase inhibitor (MONARCH-3) or with fulvestrant following progression after endocrine therapy (ET) (MONARCH-2). However, there is limited data on safety and tolerability of abemaciclib plus ET in the metastatic BC setting among Indian patients, which the present study aims to address.

Materials and Methods An open-label, single-arm, phase IV study was conducted across 16 centers in India to assess the safety and tolerability of abemaciclib in patients with HR +/HER2– locally advanced or metastatic BC. Patients were assigned to either cohort A, ET-naive patients (abemaciclib + anastrozole/letrozole) or cohort B, patients progressing after previous ET (abemaciclib + fulvestrant), targeting the same patient population as the global phase III MONARCH-3 and MONARCH-2 trials, respectively. Primary endpoints were all-cause adverse events (AEs) including serious AEs (SAEs).

Statistical Analysis The statistical analysis was conducted using SAS Version 9.4.

Results Two hundred patients were enrolled, with a mean age of 54 years, most (77.0%) were aged ≤ 65 years. The median duration of exposure was similar in both cohorts (cohort A vs. B: 24.3 vs. 24.4 weeks). Overall, 75.5 % of patients reported all-cause AEs, of which 38.5% of the patients reported AEs Common Terminology Criteria for Adverse Events grade 3 and above. The most common grade 3 and above all-cause AEs for abemaciclib were neutropenia (19.0%), followed by anemia (14.0%) and diarrhea (5.5%). Fourteen (7.0%) patients encountered SAEs, including infections (2.0%) and gastrointestinal disorders (1.5%). Most of the patients continued their treatments with appropriate dose reductions (25.5%) and dose omissions (40.5%), and only 2.5% of patients discontinued study treatment due to treatment-related AEs.

Conclusion Abemaciclib in combination with ET was found to have an acceptable tolerability in Indian patients with HR +/HER2– advanced and metastatic BC, consistent with the established safety data as reported in the pivotal global studies. No new clinical safety concerns were identified, with most of the reported AEs and SAEs managed by dose adjustments.

Authors' Contributions

All authors contributed significantly to the study. D.C.D., T.M., R.N., S.C.T., R.T., S.P., A.T. M., M.J., D.M., P.N.M. and S.G. were involved in the acquisition and interpretation of data, critical revision of the manuscript, and approval of the final version of the manuscript. S.G. also contributed to the acquisition and interpretation of data, critical revision of the manuscript, and approval of the final version. K.N.S. played a key role in interpreting the results, preparing the manuscript draft, and approving the final version. A.P. and R.A. contributed to the conception and design of the study, interpretation of the data, critical revision of the manuscript, and approval of the final version. All authors have approved the final manuscript.


Ethical Approval and Statement of Conforming to the Declaration of Helsinki

The study's protocol (I3Y-IN-JPEC) received approval from the ethics committees of all the participating centers. It adhered to ethical principles from international guidelines such as the Declaration of Helsinki, the Council for International Organizations of Medical Sciences (CIOMS), and the International Conference on Harmonisation's (ICH) Good Clinical Practice (GCP) guidelines, in addition to relevant laws and regulations (Clinicaltrials.gov - NCT04707196; Clinical Trials Registry - India (CTRI) - CTRI/2020/12/030021). All patients provided written informed consent before enrollment.


Supplementary Material



Publication History

Received: 16 September 2024

Accepted: 07 January 2025

Article published online:
31 January 2025

© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India